The gene therapy company is undergoing a restructure that will reduce headcount by 65%, or 300 roles. Those cuts include the recent sale of a Massachusetts manufacturing facility to Genezen. The restructure is expected to be complete in the fourth quarter of this year and slash recurring costs by 40%, or $75 million annually.
https://www.fiercebiotech.com/biotech/biotechs-streamline-operations-and-cut-costs-layoffs-uniqure-arbutus-and-hillevax